ライフサイエンスコーパス: liver transplantation

1 y (=death or delisted for being too sick for liver transplantation).

2 rapidly becoming the leading indication for liver transplantation.

3 IV HB who otherwise would be candidates for liver transplantation.

4 patients with progressive disease undergoing liver transplantation.

5 risk factors for cardiovascular events post-liver transplantation.

6 ood loss and transfusion requirements during liver transplantation.

7 Two cases resulted in death and 1 case in liver transplantation.

8 espite SVR12 to DAAs for HCV infection after liver transplantation.

9 or of graft survival in MELD of 40 or higher liver transplantation.

10 atocellular damage and improving outcomes in liver transplantation.

11 e transplantation is an alternative to whole liver transplantation.

12 that predict HCC recurrence after orthotopic liver transplantation.

13 erate liver regeneration in recipients after liver transplantation.

14 noma (HCC) and increasingly an indicator for liver transplantation.

15 ants isolated from patients before and after liver transplantation.

16 d one individual was successfully treated by liver transplantation.

17 them the tumor burden extent contraindicated liver transplantation.

18 ancer (HCC) is an established indication for liver transplantation.

19 m CNI to mTORi-based immunosuppression after liver transplantation.

20 advantages and disadvantages of living donor liver transplantation.

21 a bridge or even alternative to whole-organ liver transplantation.

22 15% died or were delisted and 28% underwent liver transplantation.

23 quently during the first few weeks following liver transplantation.

24 potential spontaneous recovery or bridge to liver transplantation.

25 us (HCV) infection is a major indication for liver transplantation.

26 may be associated with HCC recurrence after liver transplantation.

27 with decompensated cirrhosis before or after liver transplantation.

28 ctory to drug therapy and require orthotopic liver transplantation.

29 live), including a patient who had undergone liver transplantation.

30 disease that can be lethal in the absence of liver transplantation.

31 ad undetectable serum HCV RNA at the time of liver transplantation.

32 ed maintenance immunosuppression after adult liver transplantation.

33 -B) or CTP-C cirrhosis who had not undergone liver transplantation.

34 year-old severely affected patient underwent liver transplantation.

35 ion points to increase waitlist priority for liver transplantation.

36 was estimated in patients who had emergency liver transplantation.

37 failure to identify those needing emergency liver transplantation.

38 nd POPH have major clinical implications for liver transplantation.

39 ional guideline in the field of living donor liver transplantation.

40 predictive value for tumor recurrence after liver transplantation.

41 of end-stage liver disease that necessitates liver transplantation.

42 a fatal outcome or the need for an emergency liver transplantation.

43 ds is prevention of disease recurrence after liver transplantation.

44 important cause of morbidity after pediatric liver transplantation.

45 for patients with chronic hepatitis B after liver transplantation.

46 n patients with cirrhosis in preparation for liver transplantation.

47 lar carcinoma and the leading indication for liver transplantation.

48 al hypertension, and eventually avoidance of liver transplantation.

49 Geographic disparities persist in access to liver transplantation.

50 ring therapy, stem-cell transplantation, and liver transplantation.

51 and/or symptomatic disease are eligible for liver transplantation.

52 ld significantly increase the donor pool for liver transplantation.

53 firmed in patients who experienced AKI after liver transplantation.

54 ions and graft survival after deceased donor liver transplantation.

55 , 3 FIC1, and 6 BSEP) subsequently underwent liver transplantation.

56 mivudine (LAM) resistance (LAM-R) undergoing liver transplantation.

57 treatment might bridge to liver recovery or liver transplantation.

58 esection, radiofrequency ablation (RFA), and liver transplantation.

59 SVR 12 in patients with HCV recurrence after liver transplantation.

60 to the timing of treatment: before or after liver transplantation?

61 composite endpoints 1 (PSC-related death and liver transplantation), 2 (liver transplantation), and 3

62 only variables routinely available prior to liver transplantation, a validated model of posttranspla

63 Twenty patients underwent liver transplantation after NMP.

64 le (ABOi) dual-graft (DG) adult living donor liver transplantation (ALDLT) is not commonly performed

65 (44%) underwent SLKT, and 15 (5%) underwent liver transplantation alone.

66 anced HCC who are appropriate candidates for liver transplantation; alpha-fetoprotein level limitatio

67 factors have generated increased demand for liver transplantation among older patients.

68 %) survived: 19 were successfully bridged to liver transplantation and 7 spontaneously recovered.

69 esses underlying acute cellular rejection in liver transplantation and help clarify the potential uti

70 decline in patients with cirrhosis awaiting liver transplantation and its association with waiting l

71 ver, alterations in the gut microbiome after liver transplantation and the implications for liver tra

72 rrence and overall survival after orthotopic liver transplantation and to identify factors that predi

73 -five patients were potential candidates for liver transplantation and were considered for it upon de

74 ajor source of morbidity and mortality after liver transplantation and will likely increase given the

75 y is critical for planning liver resections, liver transplantations and complex biliary reconstructiv

76 related death and liver transplantation), 2 (liver transplantation), and 3 (liver-related events), wa

77 0 PSC-related deaths), 31 patients underwent liver transplantation, and 35 patients experienced one o

78 cirrhosis, hepatic decompensation, need for liver transplantation, and both liver-related and all-ca

79 1 patient from the Middle East who underwent liver transplantation, and compared it with other orthoh

80 ovements in outcome independent of emergency liver transplantation, and constrained by static binary

81 ariceal bleeding), hepatocellular carcinoma, liver transplantation, and liver-related death developed

82 nths of TIPS (10 patients died, one required liver transplantation, and nine increased the MELD score

83 ease course, the only available treatment is liver transplantation, and risk for disease recurrence r

84 cellular carcinoma (HCC) who were bridged to liver transplantation, and to produce an optimized pretr

85 pulmonary hypertension; IV. Implications for liver transplantation; and V.Suggestions for future clin

86 Even though auxiliary partial orthotopic liver transplantation (APOLT) as a technique was popular

87 The most frequent indications for liver transplantation are alcoholic liver disease, hepat

88 ic options to prevent graft infection during liver transplantation are emerging.

89 New treatment options, including liver transplantation, are being tested in trials and re

90 We propose liver transplantation as a new therapy for MNGIE.

91 e progressed to acute liver failure, leaving liver transplantation as the only viable treatment optio

92 unctional status of T cells before and after liver transplantation, as shown by PD-1 and Tim-3 expres

93 ta that are associated with survival without liver transplantation at 90 and 180 days after initiatio

94 Consecutive outpatients listed for liver transplantation at a single transplant center with

95 r transplantation (LDLT) or brain-dead donor liver transplantation (BDLT) across 5 French liver trans

96 to identify patients with HCC who underwent liver transplantation between 2002 and 2013.

97 with hepatocellular carcinoma who underwent liver transplantation between Jan 1, 2002, and Oct 31, 2

98 ing hepatitis B virus (HBV) recurrence after liver transplantation, but early conversion to subcutane

99 rtality and the number of patients requiring liver transplantation, but more screening campaigns are

100 Liver transplantation candidates experience significant

101 cipal aim of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study was to study hepatic

102 enrolled in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study, including 233 (85.0%

103 des cohort of patients with cirrhosis before liver transplantation (cohort A) and a cohort of postliv

104 Using the Studies of Pediatric Liver Transplantation database, we identified 2330 child

105 , which is impacted by both donor supply and liver transplantation demand.

106 oped severe hypereosinophilia 11 years after liver transplantation due to biliary atresia.

107 t one dose of study drug and did not undergo liver transplantation during treatment were included in

108 had increased incidence of infections after liver transplantation, especially within the first 90 da

109 landscape and our understanding of AILDs and liver transplantation evolves, there remain areas of unm

110 important cause of death and indication for liver transplantation (fatality).

111 eric products in individuals after kidney or liver transplantation following current FDA bioequivalen

112 Society, was convened to write guidelines on Liver Transplantation for Alcoholic Liver Disease to sum

113 the liver transplant waitlist or undergoing liver transplantation for chronic HCV infection to be de

114 fective at preventing HBV reactivation after liver transplantation for chronic hepatitis B, with a du

115 the liver transplant waitlist or undergoing liver transplantation for HCC, proportions of those with

116 severe HCV recurrence in patients undergoing liver transplantation for HCV liver disease.

117 Registry comprised data of 73 recipients of liver transplantation for hepatic trauma performed in 37

118 m of this study was to assess the results of liver transplantation for hepatic trauma.

119 ore in predicting overall survival following liver transplantation for hepatocellular carcinoma.

120 for assessment of overall survival following liver transplantation for hepatocellular carcinoma.

121 e model we developed (Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma; HALT

122 dications, selection process, and results of liver transplantation for liver tumours in children, and

123 , making it a safe alternative to orthotopic liver transplantation for patients with a wide range of

124 e originally defined in the context of adult liver transplantation for patients with hepatocellular c

125 Five patients died and 2 others underwent liver transplantation for progressive cholestasis despit

126 the liver transplant waitlist, or undergoing liver transplantation, for CLF, there was a significant

127 All patients who underwent liver transplantation from January 2000 to April 2009, h

128 Similarly, individual cases of HIV-to-HIV liver transplantation from the United Kingdom and Switze

129 lthough ALD and NAFLD recur frequently after liver transplantation, graft loss from disease recurrenc

130 AA) agents for recurrent HCV infection after liver transplantation had occult HCV infections.

131 tructing stricture-related disease, and even liver transplantation has a risk of disease recurrence.

132 Primary liver transplantation has been advocated as surgical tre

133 Liver transplantation has improved dramatically over the

134 past two decades, the use of HCV+ organs for liver transplantation has tripled.

135 ime-varying Cox proportional hazards models, liver transplantation (hazard ratio [HR], 0.22; 95% CI,

136 urgical resection after chemotherapy or with liver transplantation if local invasion and multifocalit

137 r transplantation is the predominant form of liver transplantation in India and in most Asian countri

138 The role and indications for emergency liver transplantation in paracetamol-induced acute liver

139 teria for determining the appropriateness of liver transplantation in patients with hepatocellular ca

140 graft loss from recurrent hepatitis B after liver transplantation in patients with preexisting LAM r

141 of this study was to examine the outcomes of liver transplantation in recipients with a MELD of 40 or

142 Orthotopic liver transplantation in the mouse is a powerful researc

143 xpected to become the leading indication for liver transplantation in the next decade.

144 Despite the efficacy of orthotopic liver transplantation in the treatment of end-stage live

145 eading cause of hepatocellular carcinoma and liver transplantation in the United States.

146 worldwide, and it is the number 1 reason for liver transplantation in the United States.

147 with hepatitis C virus (HCV) infection after liver transplantation include the use of ribavirin (RBV)

148 ular carcinoma continues to increase, making liver transplantation increasingly common.

149 These results clearly indicate that liver transplantation is a viable therapeutic option for

150 Liver transplantation is an effective treatment for end-

151 Conversion from CNI to mTORi after liver transplantation is associated with improved renal

152 Living donor liver transplantation is mainly restricted to pediatric

153 hypereosinophilic syndrome in patients after liver transplantation is rare, and a broad differential

154 The number of donor organs suitable for liver transplantation is restricted by cold preservation

155 Liver transplantation is the most extreme form of surgic

156 Liver transplantation is the only effective therapy for

157 Live donor liver transplantation is the predominant form of liver t

158 organ supply, and in many parts of the world liver transplantation is unavailable.

159 ric chronic liver disease and indication for liver transplantation, is similar in children and adults

160 t of anastomosis strictures after live donor liver transplantation (LDLT) because they can occlude se

161 , uniqueness, and challenges of living donor liver transplantation (LDLT) in Latin America.

162 in right hepatectomy (LRH) for living donor liver transplantation (LDLT) is a controversial issue.

163 Centers offering adult living donor liver transplantation (LDLT) mostly use right lobe graft

164 ular carcinoma (HCC) listed for living donor liver transplantation (LDLT) or brain-dead donor liver t

165 to predict HCC recurrence after living donor liver transplantation (LDLT).

166 de Milan criteria (MC) may be candidates for liver transplantation (LT) after successful downstaging.

167 ncident end-stage renal disease (ESRD) after liver transplantation (LT) and resource utilization usin

168 ses of hepatic artery thrombosis (HAT) after liver transplantation (LT) are multifactorial, early HAT

169 ith PVT and its impact on outcomes following liver transplantation (LT) are not well defined.

170 ocellular carcinoma (HCC) who are listed for liver transplantation (LT) are often treated while on th

171 n progress eventually to cirrhosis requiring liver transplantation (LT) before the age of 40.

172 ions in the early postoperative period after liver transplantation (LT) between donation after circul

173 in June 2013 to improve equity in access to liver transplantation (LT) between patients with fulmina

174 locate livers to patients with HCC requiring liver transplantation (LT) but do not include objective

175 hypertension (PoPH) is diagnosed in 2-6% of liver transplantation (LT) candidates.

176 Most pediatric liver transplantation (LT) centers administer long cours

177 C) may be at higher risk of malignancy after liver transplantation (LT) compared to other LT recipien

178 The demand for liver transplantation (LT) exceeds supply, with rising w

179 Women with cirrhosis awaiting liver transplantation (LT) experience higher rates of wa

180 virus (HIV) infection on patients undergoing liver transplantation (LT) for hepatocellular carcinoma

181 with hepatocellular cancer (HCC) waiting for liver transplantation (LT) has been developed from a lon

182 staging of hepatocellular carcinoma prior to liver transplantation (LT) has generated a lot of intere

183 arcinoma (HCC) recurrence and survival after liver transplantation (LT) in patients meeting Milan cri

184 HCC) recurrence is an alternative to primary liver transplantation (LT) in selected patients with HCC

185 rhosis is the fastest growing indication for liver transplantation (LT) in the United States.

186 efficacy at preventing HCV recurrence after liver transplantation (LT) in the United States.

187 d decompensated cirrhosis in those requiring liver transplantation (LT) is a challenging dilemma.

188 Graft-versus-host-disease (GVHD) after liver transplantation (LT) is a deadly complication with

189 Frequency of liver transplantation (LT) is increasing in nonalcoholic

190 Immunosuppression after liver transplantation (LT) is presently based on use of

191 Liver transplantation (LT) is rarely indicated in the ma

192 with hepatocellular cancer (HCC) waiting for liver transplantation (LT) is still ongoing.

193 Although the value of liver transplantation (LT) is well established, its plac

194 Whether it is able to predict early post-liver transplantation (LT) mortality in cirrhotic patien

195 ejection, fibrosis progression, and death in liver transplantation (LT) recipients with preformed or

196 gainst hepatitis B virus (HBV) recurrence in liver transplantation (LT) recipients, but HBIG is costl

197 To evaluate the whole experience of liver transplantation (LT) with donors >/=70 years in a

198 Despite reports of successful liver transplantation (LT) with elderly grafts (EG), adv

199 ween healthcare utilization before and after liver transplantation (LT), and its association with cen

200 atocellular carcinoma (HCC) recurrence after liver transplantation (LT), but no reliable risk score h

201 disease is a significant complication after liver transplantation (LT), but the role of pre-existing

202 In children, after having liver transplantation (LT), it is important to assess th

203 m hypotension and pressor use related to the liver transplantation (LT), may cause worse outcomes in

204 hich incorporates alpha-fetoprotein (AFP) at liver transplantation (LT), microvascular invasion, and

205 e is the second most frequent indication for liver transplantation (LT), yet as many as 90% to 95% of

206 timing of therapy in the context of possible liver transplantation (LT).

207 tis C (CHC) remains a leading indication for liver transplantation (LT).

208 a significant problem during evaluation for liver transplantation (LT).

209 with great impact on long-term outcome after liver transplantation (LT).

210 r morbid obesity to be a contraindication to liver transplantation (LT).

211 r the need for early retransplantation after liver transplantation (LT).

212 HAT) increases morbidity and mortality after liver transplantation (LT).

213 h (DCD) donor pool remains underutilized for liver transplantation (LT).

214 ge liver disease is the major indication for liver transplantation (LT).

215 consistent with published data on DCD use in liver transplantation (LT).

216 ent hepatocellular carcinoma (HCC) following liver transplantation (LT).

217 of recurrent hepatocellular carcinoma after liver transplantation (LT).

218 model for end-stage liver disease system for liver transplantation (LT).

219 an cause progressive liver disease requiring liver transplantation (LT).

220 um difficile infection (CDI) is common after liver transplantation (LT); however, few studies have ex

221 coming an increasingly common indication for liver transplantation (LT); however, relatively little i

222 ients improved spontaneously and 7 worsened (liver transplantation [LT] (n=5), deceased (n=2)).

223 based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellul

224 Liver transplantation (LTx) has been performed for hered

225 +TcM) predict acute cellular rejection after liver transplantation (LTx) or intestine transplantation

226 rimary sclerosing cholangitis (PSC) or after liver transplantation (LTx) remains elusive.

227 with body composition changes shortly after liver transplantation (LTx), including the influence of

228 (40%), including seven of those treated with liver transplantation (LTX).

229 llow for delayed renal transplantation after liver transplantation may prevent loss of scarce renal a

230 Setup of the orthotopic liver transplantation model comprises three main stages:

231 Organ Sharing on adults who were listed for liver transplantation (N = 122,606) or underwent liver t

232 r transplantation (N = 122,606) or underwent liver transplantation (N = 60,820) from 2002 to 2014 in

233 Applied to patients who underwent emergency liver transplantation (n=116), median predicted 30-day s

234 ntraoperative hemodynamic data in orthotopic liver transplantation (OLT) can aid in the prediction of

235 ly shown that patients listed for orthotopic liver transplantation (OLT) in United Network for Organ

236 rterial abnormalities (DAA) after orthotopic liver transplantation (OLT) often represent a sign of he

237 le to expanding the donor pool in orthotopic liver transplantation (OLT).

238 of morbidity and mortality after orthotopic liver transplantation (OLT).

239 whereas the 36-year-old underwent emergency liver transplantation on study day 2.

240 The primary and secondary endpoints were liver transplantation or death (LTD) and hepatopancreato

241 ubin (DB) <2 mg/dL, and treatment failure as liver transplantation or death while DB was >2 mg/dL as

242 bilirubin levels correlate with the risk of liver transplantation or death.

243 eatment without renal replacement therapy or liver transplantation) or SCr at or above baseline on da

244 ere followed until last clinical evaluation, liver transplantation, or death.

245 After 1 year of liver transplantation, over 90% of the patients had unde

246 propensity matched cohort was greater after liver transplantation (P </= 0.017).

247 Liver transplantation patients had lower maximal oxygen

248 pigs subjected to renal transplantation and liver transplantation patients that developed AKI.

249 ensated cirrhosis, hepatocellular carcinoma, liver transplantation, post-liver transplant, and death)

250 Data indicate that liver transplantation prolongs survival times of patient

251 Intensive care and liver transplantation provide support and rescue, respec

252 urgeons, Endoscopy, Archives of Surgery, and Liver transplantation), published between July 2013 to J

253 One hundred twenty liver transplantation recipients from across Canada with

254 s minimize FTR, will have value to pediatric liver transplantation recipients.

255 V) infection with advanced cirrhosis or post-liver transplantation recurrence represents a high unmet

256 ng donor and recipient risks in living donor liver transplantation remains an issue of debate.

257 Outcomes were receipt of active HCC therapy (liver transplantation, resection, local ablation, transa

258 nued from selected and stable patients after liver transplantation resulting in spontaneous operation

259 this, human livers of ALF patients requiring liver transplantation reveal increased CD68(+) hepatic m

260 r OLT, the Cardiovascular Risk in Orthotopic Liver Transplantation risk score, among a cohort of 1,02

261 .756-0.771), whereas survival outcomes after liver transplantation score obtains an AUC-ROC of 0.638

262 Liver transplantation seems to be justified in selected

263 However, preparation of backup liver transplantation should be considered in selected c

264 this study is to evaluate the role of split liver transplantation (SLT) in a combined pediatric and

265 h curative intent (CLRT) followed by salvage liver transplantation (SLT) in case of hepatocellular ca

266 r), upfront liver resection (LR) and salvage liver transplantation (SLT) in case of recurrence may ha

267 The salvage liver transplantation (SLT) strategy was conceived for i

268 with great success including those awaiting liver transplantation, therapy has been extended to pati

269 With the exception of liver transplantation, there is no cure for hemophilia,

270 Liver transplantation therefore results in a unique meet

271 apamycin inhibitors (mTORi) is often used in liver transplantation to overcome calcineurin inhibitor

272 gans has led to a search for alternatives to liver transplantation to restore liver function and brid

273 s and end-stage liver disease, which require liver transplantation to survive.

274 een proposed as an alternative to orthotopic liver transplantation to treat metabolic liver diseases.

275 Liver transplantation using donation after circulatory d

276 This first report of liver transplantation using NMP-preserved livers demonst

277 We evaluated liver transplantation waitlist and posttransplantation o

278 prevalence in the population with data from liver transplantation waitlists to evaluate changes in t

279 Results The rate of tumor recurrence after liver transplantation was 11.5% (321 of 2794), which sig

280 Orthotopic liver transplantation was performed using steatotic live

281 f 1300 patients who underwent deceased donor liver transplantation was performed.

282 antation Society Guidelines for Living Donor Liver Transplantation was published in July 2015 and is

283 therapy with resolution of cholestasis, and liver transplantation was rarely required.

284 d antiviral therapy for HCV recurrence after liver transplantation was well tolerated, with an overal

285 The median survival time, censored to liver transplantation, was 17.7 months for the cTACE gro

286 ecimens from patients with HCC who underwent liver transplantation, we found a sharp and significant

287 deterioration of the disease, 8 months after liver transplantation, we observed striking neurological

288 irological load refractory to LAM undergoing liver transplantation were included, with a median follo

289 ergone curative-intent ablation, surgery, or liver transplantation were positive.

290 ssion (n = 5529) without concurrent or prior liver transplantation were selected.

291 er disease, the only option for treatment is liver transplantation, whereas AAT replacement therapy i

292 mens from 55 patients at least 3 years after liver transplantation who developed rejection during tri

293 in liver explants from 39 patients awaiting liver transplantation who were treated with an interfero

294 patients with recurrent HCV infection after liver transplantation who were treated with DAAs, with o

295 The aim was to compare outcomes after liver transplantation with either younger or older donor

296 ell-compensated HCV(+) cirrhotics listed for liver transplantation with hepatocellular carcinoma MELD

297 mpensated HCV-infected cirrhotics listed for liver transplantation with hepatocellular carcinoma, eve

298 Consecutive adults listed for liver transplantation with laboratory Model for End-Stag

299 utcomes continue to improve after kidney and liver transplantation, with 1-year survival rates over 8

300 ma (HCC) patients, to try to obviate upfront liver transplantation, with the "safety net" of SLT in c